Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in (Q84904774)

From Wikidata

Jump to navigation Jump to search

scientific article published on 31 August 2012

Language	Label	Description	Also known as
English	Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in	scientific article published on 31 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

V Goede

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

K Fischer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

R Busch

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

U Jaeger

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M-S Dilhuydy

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

N Wickham

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S De Guibert

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M Ritgen

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

A W Langerak

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Bieska

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

A Engelke

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

K Humphrey

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M Wenger

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M Hallek

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

31 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1172-1174

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22936013%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the Cumulative Illness Rating Scale in a geriatric residential population

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.252

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84904774&oldid=2234032778"